Skip to main content
Vistin Pharma logo

Vistin Pharma — Investor Relations & Filings

Ticker · VISTN ISIN · NO0010734122 LEI · 5967007LIEEXZXFQY092 OL Manufacturing
Open in API
Filings indexed 519 across all filing types
Latest filing 2023-02-17 Earnings Release
Country NO Norway
Listing OL VISTN

About Vistin Pharma

https://www.vistin.com/

Vistin Pharma is a pharmaceutical company specializing in the production of Metformin Hydrochloride, an Active Pharmaceutical Ingredient (API). The company operates as a pure-play, global supplier, providing high-quality Metformin to pharmaceutical companies worldwide. In addition to the standard API, Vistin Pharma offers specialized grades such as Direct Compressible (DC) Metformin. With over 50 years of experience, the company emphasizes sustainable manufacturing from its dedicated European production facility.

Recent filings

Filing Released Lang Actions
Vistin Pharma ASA: Fourth quarter and preliminary 2022 financial results
Earnings Release Classification · 99% confidence The document is explicitly titled "4TH QUARTER REPORT AND PRELIMINARY FINANCIALS FOR 2022" and contains detailed financial statements (Revenue, COGS, EBITDA, Balance Sheet, Cash Flow) prepared according to IFRS and IAS 34 for interim financial reporting. This structure and content strongly indicate a comprehensive financial report covering a period shorter than a full year (Q4 2022). This aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it contains some CSR/ESG information, the primary focus and structure are financial reporting for a period, making IR the most accurate classification over SR. Q4 2022
2023-02-17 English
Vistin Pharma ASA: Fourth quarter and preliminary 2022 financial results
Earnings Release Classification · 100% confidence The document explicitly announces the 'Fourth quarter and preliminary 2022 financial results' and provides key financial highlights (revenue, EBITDA, net profit) for Q4 2022. This content structure strongly indicates an Earnings Release (ER). However, the final sentence states, 'Please find the Q4 report and presentation enclosed. The report will also be made available on www.vistin.com'. This suggests the document itself is the initial announcement summarizing the results, rather than the comprehensive report (which would likely be classified as IR if it were the full document). Since it is the initial announcement of periodical financial results, ER is the most appropriate classification. The document is short and serves to release the key figures ahead of a conference call. Q4 2022
2023-02-17 English
Vistin Pharma ASA: Invitation to Q4 2022 conference call
Call Transcript Classification · 95% confidence The document is titled "Vistin Pharma ASA: Invitation to Q4 2022 conference call" and explicitly states that the company will release its Q4 2022 results on February 17, 2023, and will host a conference call with a Q&A session on the same day. This document is an invitation and announcement for an earnings-related conference call, not the transcript itself, nor the full earnings release. Since the primary purpose is to announce the call details (date, time, access links) related to the release of periodic financial results, it strongly aligns with the purpose of a Call Transcript (CT) announcement or, more accurately, an announcement related to the earnings event. However, the definition for 'Call Transcript' (CT) is 'Full text transcript of company conference calls (like earnings calls with Q&A)'. Since this is an *invitation* to the call, and not the transcript, and it is directly tied to the release of periodic results, it is most closely related to the earnings event. Given the options, if the actual transcript or the earnings release (ER) is not provided, an invitation to the earnings call is often classified as a Call Transcript (CT) if the call is the main event being announced, or sometimes as a Regulatory Filing (RNS) if it's a simple announcement. Since the content heavily focuses on the upcoming conference call structure (Q&A session, webcast links), 'CT' is the most contextually relevant category for an earnings call announcement, even though it's not the transcript itself. If 'RPA' (Report Publication Announcement) were used, it would typically announce the *report*, not the *call*. Given the focus on the 'conference call', CT is the best fit among the specific options provided for an earnings-related call announcement.
2023-02-10 English
Financial calendar
Report Publication Announcement Classification · 99% confidence The document is titled 'Financial calendar' and lists scheduled dates for various corporate events and reports for Vistin Pharma ASA, including Quarterly Reports, Half-yearly Report, Annual Report, and Annual General Meeting (AGM). Since this document is a schedule or calendar of future/past events rather than the actual report or announcement of a specific event's outcome, it does not fit neatly into the specific categories like 10-K, ER, IR, or AGM-R. It is a general corporate update regarding reporting timelines. Given the options, this type of scheduling information is best categorized as a general Regulatory Filing (RNS) or potentially a miscellaneous corporate update, as it doesn't directly correspond to the definitions provided for the other specific codes. Given its nature as a schedule of mandatory disclosures, RNS is the most appropriate fallback.
2022-12-14 English
Vistin Pharma enters into a long-term renewable energy supply agreement with Statkraft
Regulatory Filings Classification · 95% confidence The document is a short announcement dated December 9, 2022, detailing a specific business agreement between Vistin Pharma and Statkraft regarding a long-term renewable energy supply. It is not a comprehensive financial report (like 10-K or IR), an earnings release (ER), or a management discussion (MDA). It concerns a significant operational/commercial arrangement that impacts future costs and competitiveness. Since it doesn't fit the specific categories like DIV, DIRS, or CAP (it's an operational contract, not financing/capital change), and it is a direct announcement of a material event, it best fits the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, or potentially a general 'LTR' if viewed as a material contract update, but RNS is the most appropriate fallback for non-standard material news releases that aren't explicitly defined elsewhere.
2022-12-09 English
Vistin Pharma ASA: Third quarter and YTD 2022 financial results
Investor Presentation Classification · 95% confidence The document text contains detailed financial performance metrics for the 'Third quarter and YTD 2022 results', including revenue, EBITDA, balance sheet figures (as of 30.09.2022), and operational updates related to the Metformin Expansion Project (MEP). It presents key highlights, operational review, and financial tables comparing Q3 2022 results against Q3 2021 and YTD figures. This structure is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it includes comprehensive tables for the Income Statement and Balance Sheet, it goes beyond the 'key highlights only' definition of an ER and aligns more closely with a comprehensive quarterly report. However, the document is presented as a presentation/slideshow format (indicated by 'Agenda', 'Highlights', 'Appendix', and the overall layout) summarizing the period, which often accompanies an Earnings Release or is a standalone Investor Presentation (IP). Given the date (26 October 2022) and the focus on Q3 results, it is most likely the material used for the earnings call. Since it contains detailed financial statements (Income Statement, Balance Sheet), it is more comprehensive than a typical ER, but less comprehensive than a full statutory IR filing. In many contexts, this presentation material accompanying the release of quarterly results is classified as an Investor Presentation (IP) or sometimes an Earnings Release (ER). Because it details the results and outlook in a presentation format, IP is a strong candidate. However, the presence of full comparative financial tables (Income Statement, Balance Sheet) suggests it contains the core data released during the earnings announcement period. Given the options, and recognizing this is the presentation deck used to discuss the quarterly results, it fits best as an Investor Presentation (IP) which often includes the core financial data discussed during the earnings call, or an Earnings Release (ER) if it is the primary document announcing the results. Since it is a presentation deck structure, IP is the most precise fit for this format, detailing strategy and financials for investors. If it were a formal regulatory filing document, IR would be chosen. Given the context of a presentation deck summarizing Q3 results, IP is selected.
2022-10-26 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.